(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada…
Search results for: cytokine storm
Enemy at the Gates: The Emerging Threat of COVID-19
On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…
New Options Emerge for Treating Macrophage Activation Syndrome
ATLANTA—Macrophage activation syndrome (MAS), a subset of hemophagocytic lymphohistiocytosis (HLH) disease, can be a fatal result of rheumatic disease. But there’s good news: New therapeutic options for refractory MAS targeting individual cytokines are emerging. At the 2019 ACR/ARP Annual Meeting, possible therapeutic options were presented during a pediatric-focused clinical and translational research track, Therapeutic Approaches…
Predicting the Unpredictable – Taming the Impulse to Treat
One of my fellows could take better care of his patients if it weren’t for the attendings getting in his way. Or so he tells me. I can hear the howls of protest already. This statement isn’t fair—it is too broad, it doesn’t fairly depict the nuances of the situation or his point of view. First,…
2014 ACR/ARHP Annual Meeting: Macrophage Activation Syndrome
The pathogenesis of and new classification criteria for MAS
Ebola: Hemorrhagic Fever and Macrophage Activation Syndrome
Rheumatologists focus on similar clinical, laboratory findings to better
understand pathobiology of Ebola infection
Finding Opportunity Through Challenge: Q&A with Vaneet K. Sandhu, MD, FACR, RhMSUS
The COVID-19 global pandemic is forcing telemedicine-only connections with patients and bringing existing rheumatology research to a standstill. However, these challenges are spurring opportunity and innovation, according to Vaneet K. Sandhu, MD, FACR, RhMSUS, director of rheumatology clinical operations at Riverside University Health System and associate fellowship program director in rheumatology at Loma Linda University…
A Stiff Man: A Case Study in Ankylosing Spondylitis
First Appearances I watched the old man, his back painfully bent, shuffle toward the scale. A blocky rigidity draped over him. His feet seemed stuck to the floor. His head hung heavily over his chest. Observing him from the end of the hallway, instead of a face, I saw only a mound of shaggy, matted…
New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…
2015 ACR/ARHP Annual Meeting: Immune Mediators Can Impact Inflammatory Response
SAN FRANCISCO—Inflammation can be either acute or chronic, and it’s the inflammatory responses that don’t shut down normally, or resolve, that cause tissue damage in rheumatic disease. “Resolution bridges the gap between acute inflammation and adaptive immunity,” said Derek W. Gilroy, PhD, head of the Centre for Clinical Pharmacology and Professor of Immunology at University…